Insider Transactions in Q4 2021 at Xeris Biopharma Holdings, Inc. (XERS)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2021
|
Paul R Edick Director |
BUY
Open market or private purchase
|
Indirect |
20,000
+37.43%
|
$40,000
$2.28 P/Share
|
|
Nov 12
2021
|
John Patrick Shannon Jr Director |
BUY
Open market or private purchase
|
Direct |
60,000
+14.16%
|
$120,000
$2.1 P/Share
|
|
Nov 11
2021
|
Paul R Edick Director |
BUY
Open market or private purchase
|
Direct |
200,000
+19.84%
|
$400,000
$2.08 P/Share
|
|
Nov 11
2021
|
John Patrick Shannon Jr Director |
BUY
Open market or private purchase
|
Direct |
40,000
+11.63%
|
$80,000
$2.09 P/Share
|
|
Nov 10
2021
|
Steven Pieper Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+12.01%
|
$50,000
$2.0 P/Share
|
|
Oct 05
2021
|
Beth Hecht Officer |
BUY
Grant, award, or other acquisition
|
Direct |
206,366
+48.29%
|
-
|
|
Oct 05
2021
|
Kenneth Erland Johnson Officer |
BUY
Grant, award, or other acquisition
|
Direct |
89,583
+48.33%
|
-
|
|
Oct 05
2021
|
Jeffrey W Sherman Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,378
+50.0%
|
-
|
|
Oct 05
2021
|
John P. Schmid Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,659
+50.0%
|
-
|
|
Oct 05
2021
|
Steven Pieper Officer |
BUY
Grant, award, or other acquisition
|
Direct |
158,108
+47.97%
|
-
|
|
Oct 05
2021
|
Steven Prestrelski Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
494,780
+34.09%
|
-
|
|
Oct 05
2021
|
John Patrick Shannon Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
263,829
+46.14%
|
-
|
|
Oct 05
2021
|
Paul R Edick Director |
BUY
Grant, award, or other acquisition
|
Indirect |
13,430
+50.0%
|
-
|
|
Oct 05
2021
|
Paul R Edick Director |
BUY
Grant, award, or other acquisition
|
Direct |
608,064
+45.16%
|
-
|
|
Oct 05
2021
|
John Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
478,312
+50.0%
|
-
|
|
Oct 05
2021
|
Garheng Kong Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,170
+50.0%
|
-
|